Amendment #2 RFP NIH-NIAMS-BAA-05-01 INNOVATIVE THERAPIES FOR RHEUMATIC AND SKIN DISEASES

Amendment to Solicitation No.: NIH-NIAMS-05-01

Amendment No.: 2

Amendment Date: February 15, 2005

RFP Issue Date: January 14, 2005

Issued By: Contracts Management Branch

National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health One Democracy Plaza, Suite 800, MSC 4872

6701 Democracy Boulevard Bethesda, MD 20892-4872

Point of Contact: Lisa Hill, Contracting Officer

Name and Address of Contractor: N/A

The above numbered solicitation is amended as set forth below.

The hour and the date specified for receipt of offers **IS NOT EXTENDED.**

Offerors must acknowledge receipt of the amendment prior to the hour and the date specified in the solicitation or as amended, by one of the following methods:

- 1. By acknowledging receipt of this amendment on each copy of the offer submitted; or
- 2. By separate letter, telegram, or Electronic Mail to Ms. Lisa Hill (https://mail.nih.gov) which includes a reference to the solicitation and amendment numbers.
- 3. By requesting a copy of the Standard Form 30 for this amendment and completing the information requested in items 8 and 15, and returning 1 copy of the amendment; (a hard copy of this amendment, including the Standard Form 30, may be requested from Ms. Lisa Hill (hill11@mail.nih.gov)).

FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.

RFP NIH-NIAMS-BAA-05-01 is hereby amended as follows:

The following questions have come forth regarding this solicitation. Responses to the questions are provided below.

Question 1: If a DSMB is required, is it convened at the cost of the offeror or will NIAMS convene this group and cover the costs incurred by DSMB members?

Answer 1: The NIAMS will convene the group and cover the costs incurred by DSMB members. However, your proposal should budget travel for the Principal Investigator and other staff to attend DSMB meetings, as appropriate.

Question 2: Can you notify us of previous grant applications funded under a similar offering or is this the first time that this has been offered?

Answer 2: This Broad Agency Announcement was also issued in 2001 and 2 awards resulted in 2002. One award was made to Duke University Medical Center for a five year period for a study entitled "Prevention of Cardiovascular Complications of Pediatric Systemic Lupus Erythematosus (SLE): Artherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)." The other award was made to the University of Cinncinnati for a study entitled "Gabapentin in the Treatment of Fibromyalgia."